Concizumab is an anti-TFPI monoclonal antibody (IgG4 type) that selectively binds to the Kunitz protease inhibitor (KPI) 2 domain of TFPI, blocking its interaction with the FXa active site.

α-Galactosylceramide is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

Steviolbioside is a natural sweetener it presents notable inhibition on human hepatocarcinoma cell Hep3B human breast cancer cell MDA-MB-231 and human pancreatic cancer cell BxPC-3 thus steviolbioside could be a potential remedy for human breast cancer.